Table 2.
The clinical trials of immune checkpoint inhibitors.
| Inhibitory receptors | mAbs | Cancer type | Start date | phase | Status | ClinicalTrials.gov ID |
|---|---|---|---|---|---|---|
| NKG2A | Monalizumab | MSI and/or dMMR Metastatic Cancer | 2023-12 | II | Not yet recruiting | NCT06152523 |
| Small Cell Lung Cancer | 2023-09 | II | Recruiting | NCT05903092 | ||
| Non-Small Cell Lung Cancer | 2022-02 | III | Recruiting | NCT05221840 | ||
| Metastatic HER2-pOSitive breast Cancer | 2021-03 | II | Active, not recruiting | NCT04307329 | ||
| Advanced or Metastatic Cancer | 2020-04 | II | Completed | NCT04333914 | ||
| Non-Small Cell Lung Cancer | 2019-10 | I | Recruiting | NCT03801902 | ||
| Non-small Cell Lung Cancer | 2019-10 | II | Active, not recruiting | NCT03833440 | ||
| Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck | 2017-11 | II | Active, not recruiting | NCT03088059 | ||
| Head and Neck Neoplasms | 2015-12 | I/II | Completed | NCT02643550 | ||
| Chronic Lymphocytic Leukemia | 2015-11 | I/II | Terminated | NCT02557516 | ||
| PD-1 | Nivolumab | Endometrial Cancer | 2023-10 | II | Recruiting | NCT05795244 |
| Solid Tumors | 2022-11 | I | Recruiting | NCT05266612 | ||
| Hepatocellular Carcinoma | 2022-05 | II | Recruiting | NCT05257590 | ||
| Metastatic Solid Tumors | 2021-09 | II | Recruiting | NCT04957615 | ||
| Neuroendocrine Tumors or Carcinomas | 2020-06 | II | Recruiting | NCT04525638 | ||
| Pembrolizumab | Advanced Solid Tumors | 2024-07 | I/II | Recruiting | NCT06470763 | |
| Advanced Solid Tumor | 2024-05 | I/II | Recruiting | NCT06249048 | ||
| Advanced Solid Tumors | 2023-07 | I | Recruiting | NCT05996445 | ||
| Advanced Solid Tumors | 2023-03 | I | Recruiting | NCT05763004 | ||
| High-Grade Cervical Intraepithelial Neoplasia | 2021-06 | II | Recruiting | NCT04712851 | ||
| Atezolizumab | Solid Tumors | 2024-08 | I | Not yet recruiting | NCT06488716 | |
| Solid Tumors | 2023-12 | II | Recruiting | NCT06003621 | ||
| High-Risk Urothelial Carcinoma | 2023-02 | I/II | Recruiting | NCT05394337 | ||
| Advanced Solid Tumors | 2022-09 | I/II | Recruiting | NCT05450562 | ||
| Advanced Solid Tumors | 2021-09 | I/II | Recruiting | NCT04896697 | ||
| Avelumab | Gestational Trophoblastic Tumors | 2024-04 | N/A | Not yet recruiting | NCT06242522 | |
| Urothelial Cancer | 2022-12 | II | Recruiting | NCT05600127 | ||
| Breast Cancer | 2021-06 | II | Recruiting | NCT04841148 | ||
| Triple Negative Breast Cancer | 2020-08 | T | Recruiting | NCT04360941 | ||
| Gestational Trophoblastic Neoplasia | 2020-02 | I/II | Recruiting | NCT04396223 | ||
| Hodgkin Lymphoma | 2019-09 | II | Active, not recruiting | NCT03617666 | ||
| Squamous Cell Penile Carcinoma | 2019-03 | II | Recruiting | NCT03774901 | ||
| Muscle Invasive Bladder Cancer | 2018-12 | II | Recruiting | NCT03747419 | ||
| TIGIT | Etigilimab | Ovarian Cancer | 2023-03 | II | Recruiting | NCT05715216 |
| Domvanalimab | Hepatobiliary Cancers | 2023-06 | II | Recruiting | NCT05724563 | |
| Lung Cancer | 2023-03 | II | Recruiting | NCT05633667 | ||
| Pancreatic Cancer | 2022-11 | I/II | Recruiting | NCT05419479 | ||
| Non-small Cell Lung Cancer | 2022-10 | III | Recruiting | NCT05502237 | ||
| Relapsed/Refractory Melanoma | 2022-03 | II | Recruiting | NCT05130177 | ||
| Non-Small Cell Lung Cancer | 2022-02 | III | Recruiting | NCT05211895 | ||
| Glioblastoma | 2021-04 | I | Recruiting | NCT04656535 | ||
| TIM-3 | Cobolimab | Advanced Cervical Cancer | 2024-03 | II | Recruiting | NCT06238635 |
| Stage III or IV Melanoma | 2020-06 | II | Recruiting | NCT04139902 | ||
| Hepatocellular Carcinoma | 2019-12 | II | Recruiting | NCT03680508 | ||
| sabatolimab | Myelodysplastic Syndrome | 2021-05 | II | Terminated | NCT04812548 | |
| Advanced Malignancies | 2015-11 | I/II | Terminated | NCT02608268 | ||
| Sym023 | Recurrent Advanced Selected Solid Tumor Malignancies | 2020-10 | I | Completed | NCT04641871 | |
| Advanced Solid Tumor Malignancies or Lymphomas | 2018-05 | I | Completed | NCT03489343 | ||
| Advanced Solid Tumor Malignancies or Lymphomas | 2017-11 | I | Completed | NCT03311412 | ||
| KIRs | IPH4102 | Advanced T-cell Lymphoma | 2019-05 | II | Active, not recruiting | NCT03902184 |
| Relapsed/Refractory Cutaneous T-cell Lymphomas | 2015-10 | I | Completed | NCT02593045 | ||
| Lirilumab | Bladder Cancer | 2019-03 | I | Completed | NCT03532451 | |
| Squamous Cell Carcinoma of the Head and Neck | 2018-03 | II | Active, not recruiting | NCT03341936 | ||
| Advanced or Metastatic Malignancies | 2018-03 | I/II | Terminated | NCT03347123 | ||
| Advanced and/or Metastatic Solid Tumors | 2017-07 | I | Completed | NCT03203876 | ||
| Myelodysplastic Syndromes | 2016-03 | II | Terminated | NCT02599649 | ||
| Chronic Lymphocytic Leukemia | 2015-06 | II | Completed | NCT02481297 | ||
| Refractory/Relapsed Acute Myeloid Leukemia | 2015-04 | II | Terminated | NCT02399917 |